Jung Sun Kim

7PUBLICATIONS
17CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersBehavioural epidemiologyOrganisational, interpersonal and intercultural communication
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Feb 12, 2026
Response: Reassessing the Use of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC.

Jung Sun Kim, Thomas Yau, Hong Jae Chon

|Feb 02, 2026
Prognostic Value of FDG PET/CT Parameters in Patients With Advanced Biliary Tract Cancer Receiving Gemcitabine, Cisplatin, and Nab-Paclitaxel.

Jeong Won Lee, Sang Mi Lee, Beodeul Kang

|Dec 26, 2025
Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study.

Jung Sun Kim, Jeffrey Wong, San-Chi Chen

|Apr 21, 2025
Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy.

Jeong Won Lee, Sang Mi Lee, Beodeul Kang

|Jun 24, 2024
Exploring treatment options for biliary tract cancers: moving beyond the era of gemcitabine and platinum doublet.

Jung Sun Kim, Hong Jae Chon

|Nov 25, 2022
Correction: Understanding the Social Mechanism of Cancer Misinformation Spread on YouTube and Lessons Learned: Infodemiological Study.

Ho Young Yoon, Kyung Han You, Jung Hye Kwon

Pageof 2

Frequent Collaborators

5 joint publications

Hong Jae Chon

2 joint publications

Ho Young Yoon

2 joint publications

Kyung Han You

2 joint publications

Jung Hye Kwon